Dr Pol Vandenbroucke
Senior Vice President and Chief Development Officer, Pfizer Essential Health

Dr. Vandenbroucke serves on the Board of BIO Ventures for Global Health, and of the American Federation for Aging Research; He is a member of the Advisory Board of the Steve Biko Centre for Bioethics, University of the Witwatersrand, Johannesburg, South Africa, the Canadian Institutes of Health Research and the Keck Graduate Institute, Claremont, CA; and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Medicine of the United Kingdom.

A frequent speaker on health, aging, diversity and policy issues, he is also the Module Coordinator for Medical Affairs in the Medicines Development Certificate Program at IFAPP Academy and King’s College London.

Dr. Vandenbroucke’ s career has been dedicated to Clinical Development, Medical Affairs and Marketing and has included stints in the U.S., Europe, Asia, and Latin America.  Before his current position, he was responsible for Medical Strategy for Pfizer Inc. and for Medical Affairs of Pfizer’s Essential Health portfolio in North America. He previously also led the Clinical Development of all Pfizer compounds in Asia, Central/Eastern Europe, Latin America, and Africa-Middle East and of Pfizer’s Established Products globally.  He was also responsible for developing compounds specifically for diseases of the developing world, such as malaria and river blindness.

Prior appointments include Vice President, Medical and Regulatory Affairs, Canada/Latin America/Africa-Middle East, Senior Vice President, Medical Division Pfizer Japan, based in Tokyo, Director of Medical Operations, Asia and Australia/NZ for Pfizer, based in Hong Kong, and Medical Director, Lipitor based in New York, responsible for the international clinical development program of Lipitor.

Before joining Pfizer, Dr. Vandenbroucke was Medical Director, Sterling-Winthrop International; Cardiovascular and CNS Disease Manager at Novartis Mexico, and Assistant Director R&D at Procter & Gamble Mexico.

He holds a Medical Degree from the Catholic University of Louvain (Belgium), an MBA degree from the Instituto Tecnológico Autónomo de México (ITAM), and an MSc (First Honors) from Hibernia College (Ireland). He is fluent in Dutch, Spanish, English, French, German and basic Japanese.

Dr Pol Vandenbroucke